Paper Details

  1. Home
  2. Paper Details

Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment.

Author: HasselJessica C, KälberKatharina A, MachirajuDevayani, StrobelSophia B

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study investigated the safety of COVID-19 vaccines in cancer patients receiving immune-checkpoint inhibitors (ICIs). The most common side effects were mild to moderate pain at the injection site and fatigue. Grade 3 immune-related adverse events (irAEs) were reported in eight patients, seven of whom were on nivolumab plus ipilimumab combination treatment. This small cohort study suggests that approved COVID-19 vaccinations are safe for use in cancer patients receiving ICIs, but precautions should be taken regarding the timing of vaccination and ICI treatment.
Paper Details　
Original Abstract of the Article :
To date, few data are available regarding Adverse events (AEs) in cancer patients who are vaccinated for coronavirus disease 2019 (COVID-19) while being actively treated with Immune-checkpoint inhibitors (ICIs). We aimed to assess the safety of COVID-19 vaccines approved in Germany. Specifically, we...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8695667/

データ提供：米国国立医学図書館（NLM）

Navigating the COVID-19 Vaccination Landscape for Skin Cancer Patients

The COVID-19 pandemic, like a sudden desert storm, has presented numerous challenges, particularly for individuals with compromised immune systems, such as those receiving immune-checkpoint inhibitor (ICI) therapy for skin cancer. This study, like a seasoned traveler navigating a complex landscape, aims to assess the safety of COVID-19 vaccines in this vulnerable population.

COVID-19 Vaccination: A Balanced Approach for Skin Cancer Patients

The study, akin to an exploration into the depths of the desert, reveals that approved COVID-19 vaccines appear to be safe for skin cancer patients receiving ICIs, with the most common side effects being mild to moderate pain at the injection site and fatigue. However, the researchers note that some precautions should be taken, particularly concerning the timing of vaccination and ICI treatment. It's like navigating a treacherous path, where careful planning and awareness are paramount.

Immune-related Adverse Events: A Case of Timing

The study found a potential link between the timing of vaccination and ICI treatment and the occurrence of immune-related adverse events (irAEs). This finding, like a desert mirage, highlights the importance of careful consideration and coordination between healthcare providers and patients. It's a reminder that while the benefits of vaccination outweigh the risks, individual factors must be carefully assessed to optimize safety and minimize potential complications.

Dr. Camel's Conclusion

This research, like a compass guiding us through the complexities of cancer treatment and vaccination, provides valuable insights for clinicians and patients. While COVID-19 vaccines offer a crucial line of defense, understanding the nuances of their interaction with ICI therapy is essential. As a wise camel, I always advocate for thoughtful planning and a collaborative approach to healthcare, ensuring that the journey to wellness is safe and successful.

Date :
  1. Date Completed 2022-07-20
  2. Date Revised 2022-07-21
Further Info :

Pubmed ID

34940894

DOI: Digital Object Identifier

PMC8695667

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.